Department of Pathomorphology, the Children's Memorial Health Institute, Aleja Dzieci Polskich 20, 04-730 Warsaw, Poland.
Outpatient Allergology and Dermatology Clinic, Patriotów St. 100, 04-844 Warsaw, Poland.
Nutrients. 2021 Apr 1;13(4):1169. doi: 10.3390/nu13041169.
Probiotics seem to have promising effects in the prevention and treatment of allergic conditions including atopic dermatitis (AD) and food allergy. The purpose of this multicenter randomized placebo-controlled trial was to evaluate the effectiveness of a probiotic preparation comprising ŁOCK 0900, ŁOCK 0908, and ŁOCK 0918 in children under 2 years of age with AD and a cow's milk protein (CMP) allergy. The study enrolled 151 children, who-apart from being treated with a CMP elimination diet-were randomized to receive the probiotic preparation at a daily dose of 10 bacteria or a placebo for three months, with a subsequent nine-month follow-up. The primary outcomes included changes in AD symptom severity assessed with the scoring AD (SCORAD) index and in the proportion of children with symptom improvement (a SCORAD score decreased by at least 30% in comparison with that at baseline). After the three-month intervention, both the probiotic and placebo groups showed a significant ( < 0.0001) decrease in SCORAD scores, which was maintained nine months later. The percentage of children who showed improvement was significantly higher in the probiotic than in the placebo group (odds ratio (OR) 2.56; 95% confidence interval (CI) 1.13-5.8; = 0.012) after three months. Probiotics induced SCORAD improvement mainly in allergen sensitized patients (OR 6.03; 95% CI 1.85-19.67, = 0.001), but this positive effect was not observed after nine months. The results showed that the mixture of probiotic ŁOCK strains offers benefits for children with AD and CMP allergy. Further research is necessary to assess the effect of probiotic supplementation on the development of immune tolerance (NCT04738565).
益生菌似乎对预防和治疗过敏症有很好的效果,包括特应性皮炎(AD)和食物过敏。本多中心随机安慰剂对照试验的目的是评估包含 ŁOCK 0900、LOCK 0908 和 LOCK 0918 的益生菌制剂对 2 岁以下患有 AD 和牛奶蛋白(CMP)过敏的儿童的有效性。该研究纳入了 151 名儿童,他们除了接受 CMP 消除饮食外,还随机接受益生菌制剂每日 10 细菌剂量或安慰剂治疗三个月,随后进行九个月的随访。主要结局包括使用 SCORAD 评分评估 AD 症状严重程度的变化和症状改善的儿童比例(与基线相比 SCORAD 评分至少降低 30%)。在三个月的干预后,益生菌组和安慰剂组的 SCORAD 评分均显著下降(<0.0001),九个月后仍保持下降。益生菌组显示改善的儿童比例明显高于安慰剂组(比值比(OR)2.56;95%置信区间(CI)1.13-5.8;=0.012)三个月后。益生菌诱导 SCORAD 改善主要发生在过敏原致敏患者中(OR 6.03;95%CI 1.85-19.67,=0.001),但九个月后未观察到这种积极效果。结果表明,益生菌 ŁOCK 菌株混合物对患有 AD 和 CMP 过敏的儿童有益。需要进一步研究来评估益生菌补充对免疫耐受发展的影响(NCT04738565)。